Lithium regulates glycogen synthase kinase-3β in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder
X Li, AB Friedman, W Zhu, L Wang, S Boswell… - Biological …, 2007 - Elsevier
BACKGROUND: Bipolar disorder has been linked to alterations in the multifunctional
enzyme glycogen synthase kinase-3β (GSK3β). The mood stabilizer lithium inhibits GSK3β
in vitro and in mouse brain, and this is currently the strongest known potential therapeutic
target of lithium. We tested whether lithium modified GSK3β in vivo or in vitro in peripheral
blood mononuclear cells (PBMCs) from healthy control and bipolar disorder subjects.
METHODS: The PBMCs were obtained from 23 healthy control subjects, 9 bipolar subjects …
enzyme glycogen synthase kinase-3β (GSK3β). The mood stabilizer lithium inhibits GSK3β
in vitro and in mouse brain, and this is currently the strongest known potential therapeutic
target of lithium. We tested whether lithium modified GSK3β in vivo or in vitro in peripheral
blood mononuclear cells (PBMCs) from healthy control and bipolar disorder subjects.
METHODS: The PBMCs were obtained from 23 healthy control subjects, 9 bipolar subjects …